Luisa Vega
Psychiatric/Mental Health · Riverview, FLNPI 1558772657
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,312 of the $29,577 with a category attached, or 78.8%. 10 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 47.8% of the total. 2025 is the largest year on record at $27,068, more than ten times the $1,056 reported in 2021. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $197.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$14K
- Otsuka America Pharmaceutical, Inc.$13K
- Avanir Pharmaceuticals, Inc.$1K
- Neurocrine Biosciences, Inc.$400
- Teva Pharmaceuticals USA, Inc.$199
- AstraZeneca$129
- plus $283 from 4 others
What the payments were for
- Consulting fees$6002%
- Speaking & faculty fees$23,31279%
- Travel & lodging$1,7276%
- Food & beverage$3,85813%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 57 | $14,152 |
| Otsuka America Pharmaceutical, Inc. | 40 | $13,403 |
| Avanir Pharmaceuticals, Inc. | 28 | $1,011 |
| Neurocrine Biosciences, Inc. | 12 | $400 |
| Teva Pharmaceuticals USA, Inc. | 7 | $199 |
| AstraZeneca | 1 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Bioxcel Therapeutics, Inc. | 2 | $117 |
| Indivior Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,577 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 874 | $1,366,424 |
| NuplazidPimavanserin Tartrate | 200 | $1,057,376 |
| IngrezzaValbenazine Tosylate | 58 | $471,296 |
| Divalproex Sodium | 207 | $13,831 |
| RexultiBrexpiprazole | 14 | $10,418 |
| VraylarCariprazine Hcl | 12 | $8,621 |
| Gabapentin | 278 | $7,344 |
| Trazodone Hcl | 537 | $6,500 |
| Chlorpromazine Hcl | 21 | $6,398 |
| Lorazepam | 401 | $5,633 |
| Duloxetine Hcl | 98 | $4,986 |
| Quetiapine Fumarate | 196 | $4,830 |
| Zonisamide | 176 | $4,687 |
| Oxcarbazepine | 37 | $3,273 |
| Guanfacine Hcl ErGuanfacine Hcl | 60 | $3,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $1,011 | $1,366,424874 claims |
| Acadia Pharmaceuticals IncNuplazid | $14,152 | $1,057,376200 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $400 | $471,29658 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $13,403 | $10,41814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Riverview
- Candice SexilRiverview$15K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.